Biofabricated-Materials Adoption Board Adviser

The mandate

Directors repeatedly ask whether celebrated capsule products and paid trials prove a repeatable material business or only brand experimentation. Development agreements use different performance specifications, application work absorbs scarce scientists, pilot yields change by finish and design teams seek exclusivity before repeat orders exist. The adviser’s standing question is what evidence converts collaboration into adoption and when brand-specific customisation destroys the production and intellectual-property platform the board intends to scale.

The commitment is four days a month: one qualification-and-demand review, one capacity and portfolio challenge, chair preparation and either committee attendance or an evidence visit. Five committee meetings and four brand, application or pilot-line visits are included. Material exclusivity or capacity questions receive a response within forty-eight hours. Live brand negotiation, material release, claims approval, design selection and production direction remain with management and qualified experts.

The term lasts ten months through two qualification cycles and the next capacity-sanction decision. A single two-month renewal may occur if a named brand programme remains in formal validation and conflicts are refreshed. The adviser concludes with an adoption-stage model, customer evidence history, customisation boundaries and decision gates for application support, exclusivity, reserved capacity or withdrawal. The independent chair decides renewal after reviewing whether executives can apply the framework alone.

The adviser holds no line authority, executive responsibility, technical approval, transaction mandate or board vote. Scientists and quality teams approve materials, brands decide products, management negotiates and directors sanction capital. The adviser may challenge evidence, recommend a portfolio cap or staged commitment and press for repeat-order proof, but cannot certify performance, validate environmental claims, grant rights, allocate production, choose designs or represent a brand’s intent.

Relationships involving competing biomaterials companies, luxury houses, contract manufacturers, chemical suppliers, testing laboratories, sustainability certifiers, investors or prospective licensees require disclosure. A current role for a live brand counterparty normally requires recusal. Other non-conflicting positions are permitted within the stated cadence. Compensation will not vary with trials, orders, capacity sanctioned, exclusivity, claim approval, valuation or selection of any brand, supplier or production partner.

Why the board wants this voice

Science teams see technical progress, partnership leaders see brand access and investors see category creation, but none is independent of the adoption narrative. The company lacks a director who has moved novel materials through specification, design integration, repeat purchase and production learning. That voice can help the board protect optionality without dismissing the bespoke work genuinely required to establish a new material category.

What you will own

• Press management to separate introduction, funded development, qualification, product launch, repeat order and scaled adoption.
• Test brand programmes against specification stability, application effort, yield, design ownership, volume timing and switching risk.
• Challenge capacity cases where non-binding forecasts, publicity value or exclusivity requests substitute for repeat demand.
• Examine customisation boundaries that preserve shared process learning, intellectual property and manufacturable product families.
• Shape evidence gates for new collaborations, specialist allocation, exclusivity, reserved capacity and expansion capital.
• Maintain independent records of assumptions, failed tests, conflicts, brand dependencies, dissent and expired demand evidence.
• Leave the committee a repeatable adoption review linked to qualification stage and production economics.

Candidate qualifications

• Has commercialised novel performance materials through demanding brand, automotive, apparel or consumer-product qualification.
• Can evidence a capacity or exclusivity decision changed because a visible collaboration lacked repeat-order proof.
• Understands application development, specifications, pilot yield, quality, design integration, intellectual property and customer qualification.
• Has challenged founder and brand narratives without making technical, design or sustainability judgments.
• Can distinguish necessary application learning from customer-specific development work that fragments the underlying production and intellectual-property platform.
• Is independent of relevant biomaterials companies, brands, manufacturers, laboratories, certifiers, investors and licensees.

Non-negotiables

• Can attend five Montreal committee meetings and complete four controlled application, brand or pilot-line reviews.
• Will not certify material performance, claims, environmental benefit, design suitability or intellectual-property rights.
• Brings direct advanced-material adoption governance; conventional brand marketing or research investing alone is insufficient.
• Will disclose brand, supplier, manufacturer, laboratory and investor relationships before reviewing partnership evidence.

1. 49 words maximum. Which customer-development signal most overstated real adoption for a novel material you commercialised?
2. 49 words maximum. What brand, manufacturer, supplier, laboratory or investor commitments would this board need disclosed?
3. 49 words maximum. When have you limited customisation to protect a scalable material platform?